Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 3718.

https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718

Published: 2017

Journal Articles

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Sylvia Haas, MD, Alexander GG Turpie, MD, Michael Rud Lassen, MD, Ajay K Kakkar, MD, PhD, Bengt Eriksson, MD, PhD, Kai Vogtlaender, Dagmar Kubitza, MD, Wolfgang Mueck, PhD, Michael Gent, DSc, Frank Misselwitz, MD, Scott D Berkowitz, MD, FACP

Blood (2009) 114 (22): 2099.

https://doi.org/10.1182/blood.V114.22.2099.2099

Published: 2009

Journal Articles

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT).

Wolfgang Mueck, PhD, Giancarlo Agnelli, MD, Harry Buller, MD

Blood (2007) 110 (11): 1880.

https://doi.org/10.1182/blood.V110.11.1880.1880

Published: 2007

Journal Articles

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Atef Halabi, MD, Haidar Maatouk, MD, Norbert Klause, MD, Volkmar Lufft, MD, Dagmar Kubitza, MD, Michael Zuehlsdorf, PhD, Michael Becka, PhD, Wolfgang Mueck, PhD, Rafael Schäfers, MD, Dominic Wand, Thomas Philipp, MD, Heike Bruck, MD

Blood (2006) 108 (11): 913.

https://doi.org/10.1182/blood.V108.11.913.913

Published: 2006

Journal Articles

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

Wolfgang Mueck, PhD, Bengt I. Eriksson, MD, PhD, Lars C. Borris, MD, Ola E. Dahl, MD, PhD, Sylvia Haas, MD, Menno V. Huisman, MD, PhD, Ajay K. Kakkar, MD, PhD, Peter Kälebo, MD, PhD, Eva Muehlhofer, PhD, Frank Misselwitz, MD, PhD

Blood (2006) 108 (11): 903.

https://doi.org/10.1182/blood.V108.11.903.903

Published: 2006

Journal Articles

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, Michael Becka, PhD, Wolfgang Mueck, PhD, Michael Zuehlsdorf, PhD

Blood (2006) 108 (11): 905.

https://doi.org/10.1182/blood.V108.11.905.905

Published: 2006

Journal Articles

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Dagmar Kubitza, MD, Michael Becka, MD, Michael Zuehlsdorf, MD, Wolfgang Mueck, MD

Blood (2005) 106 (11): 1872.

https://doi.org/10.1182/blood.V106.11.1872.1872

Published: 2005

Journal Articles

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Dagmar Kubitza, MD, PhD, Michael Becka, MD, Wolfgang Mueck, MD, Michael Zuehlsdorf, MD

Blood (2005) 106 (11): 1873.

https://doi.org/10.1182/blood.V106.11.1873.1873

Published: 2005

NARROW

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Prothrombin Time and Bleeding Events in Patients Undergoing Total Hip or Knee Replacement Surgery Receiving 10 Mg Rivaroxaban.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein Thrombosis (DVT).

Effects of Renal Impairment on the Pharmacology of Rivaroxaban (BAY 59-7939) - An Oral, Direct, Factor Xa Inhibitor.

Rivaroxaban for Thromboprophylaxis in Patients Undergoing Total Hip Replacement: Comparison of Pharmacokinetics and Pharmacodynamics with Once- and Twice-Daily Dosing.

The Effect of Extreme Age, and Gender, on the Pharmacology and Tolerability of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor.

Effects of Single-Dose BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor - in Subjects with Extreme Body Weight.

Naproxen Has No Relevant Effect on the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 - An Oral, Direct Factor Xa Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only